FDA Grants Priority Review To Roche's Gazyva/Gazyvaro, Potential First Therapy For Primary Membranous Nephropathy, After Phase III MAJESTY Showed Superior Remission Versus Tacrolimus

Roche Reports H1 2026 Revenue Of CHF 30.4B, Up 6% At CER But Down 2% In CHF, As Core EPS Rises 9% At CER To CHF 10.85 From CHF 11.08

Roche Introduces Cobas Hepatitis D Virus Test, First Fully Automated Diagnostic Solution To Identify Most Severe Form Of Viral Hepatitis

The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis,

Roche's Phase III ATOMIC Study Drives FDA Priority Review For Tecentriq Plus Chemotherapy As Potential New Standard Of Care In Stage III dMMR/MSI-H Colon Cancer

Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone1Nearly one in three patients with stage III colon

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED)

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine, raising stakes for BioNTech & Genentech's program.